Chronic hepatitis B is a long-term liver infection caused by the hepatitis B virus (HBV) that persists for six months or longer. Unlike an acute infection, which most healthy adults clear on their own, chronic hepatitis B means the virus has settled into the liver and the immune system hasn’t been able to eliminate it. An estimated 254 million people worldwide were living with chronic hepatitis B in 2022, and the infection contributed to roughly 1.1 million deaths that year, mostly from complications like cirrhosis and liver cancer.
How It Becomes Chronic
The single biggest factor in whether hepatitis B becomes chronic is age at infection. About 90% of infants infected at birth or before age five develop a chronic infection. Their immune systems are too immature to recognize and fight the virus effectively, so it establishes a permanent foothold in liver cells. Adults who contract hepatitis B have a very different outcome: fewer than 5% develop a chronic infection. Most adults mount a strong enough immune response to clear the virus within weeks to months.
This is why mother-to-child transmission during birth is the most significant route of chronic infection globally. When the mother has a high viral load, the risk of passing the virus to her baby ranges from 70% to 90% without preventive measures. Beyond that, horizontal transmission in early childhood (through household contact, for instance) also accounts for a large share of chronic cases. In adults, the virus spreads through blood and body fluids: unprotected sex, shared needles, unsafe medical procedures, and unscreened blood transfusions.
The Four Phases of Chronic Infection
Chronic hepatitis B isn’t a single, static condition. The virus and the immune system interact in a shifting balance over years or decades, and the infection cycles through distinct phases. Not everyone passes through all four, and the phases don’t always follow a neat sequence, but understanding them helps explain why some people with chronic HBV feel fine for years while others develop serious liver damage.
Phase 1: High virus, no liver damage. The immune system largely tolerates the virus. Viral levels in the blood are extremely high, but liver enzymes (a marker of liver cell injury) stay normal. This phase is most common in people infected at birth and can last for decades. The liver remains healthy, but the person is highly infectious.
Phase 2: Immune activity and liver inflammation. The immune system begins attacking infected liver cells. Viral levels drop somewhat, but liver enzymes rise because the immune response is damaging liver tissue in the process of trying to clear the virus. This phase can cause moderate to severe liver disease and is often when treatment is considered.
Phase 3: Low virus, stable liver. The immune system has gained partial control. Viral levels fall to very low levels, liver enzymes return to normal, and the liver shows no active damage. People in this phase have a favorable outlook, though the virus isn’t gone. It persists in liver cells at low levels.
Phase 4: Reactivation. In some people, the virus flares again even after a period of immune control. Viral levels climb back up, liver enzymes rise, and active liver damage resumes. This phase can be unpredictable, with periods of flare and calm, and carries a risk of progressive scarring.
How It’s Diagnosed
A simple blood test detects a protein on the surface of the virus called HBsAg (hepatitis B surface antigen). If this marker is present in two blood samples taken at least six months apart, the infection is classified as chronic. A single positive test could reflect a new, acute infection that the body might still clear.
Additional blood tests help paint a fuller picture. A test for antibodies to the surface antigen (anti-HBs) indicates immunity, either from a past resolved infection or from vaccination. A test for core antibodies (anti-HBc) shows whether someone has ever been exposed to the virus. Measuring the actual amount of viral DNA in the blood tells doctors how actively the virus is replicating and helps determine which phase of infection a person is in.
If you’ve been vaccinated and never infected, your blood will show only anti-HBs (the protective antibody) with no other markers. If you’ve recovered from a past infection, you’ll typically have both anti-HBs and anti-HBc, with no detectable virus.
Symptoms and Daily Experience
Most people with chronic hepatitis B have no symptoms for years, sometimes decades. The virus quietly replicates in the liver without causing noticeable problems, which is why many people don’t know they’re infected until routine bloodwork or a screening test reveals it. When symptoms do appear, they tend to be vague: persistent fatigue, mild abdominal discomfort in the upper right side (where the liver sits), and occasionally joint pain.
More obvious signs like jaundice (yellowing of the skin and eyes), dark urine, and significant abdominal swelling usually indicate that the liver has already sustained considerable damage. By that point, the disease may have progressed to cirrhosis or another serious complication. This is precisely why regular monitoring matters so much for people living with chronic HBV, even when they feel perfectly healthy.
Long-Term Risks
Without treatment, roughly 1 in 4 people with chronic hepatitis B will eventually die from cirrhosis or liver cancer. These complications develop slowly over years as repeated cycles of liver inflammation and healing gradually replace healthy tissue with scar tissue.
Cirrhosis is the end stage of this scarring process. Once enough of the liver is scarred, it can no longer filter blood effectively, produce essential proteins, or perform its hundreds of other metabolic functions. Liver cancer (hepatocellular carcinoma) can develop even before full cirrhosis sets in, which is why cancer screening is recommended for many people with chronic HBV regardless of how much scarring they have.
Treatment and Monitoring
Not everyone with chronic hepatitis B needs antiviral medication right away. Treatment decisions depend on viral load, liver enzyme levels, and the degree of liver scarring. Current guidelines recommend starting treatment when viral DNA in the blood exceeds 2,000 IU/ml and liver enzymes are elevated on at least two separate occasions. Anyone with significant liver scarring (moderate fibrosis or worse) qualifies for treatment regardless of their viral load or enzyme levels.
The standard treatment uses oral antiviral drugs that block the virus from copying itself inside liver cells. These medications suppress the virus effectively in most people, bringing viral levels down to undetectable and allowing the liver to heal. The catch is that treatment is typically long-term, often indefinite. Stopping medication can allow the virus to rebound, so most people take a daily pill for years. In some cases, the virus is suppressed well enough that a doctor may consider a carefully monitored trial off medication, but this isn’t the norm.
Monitoring is a core part of living with chronic HBV whether or not you’re on treatment. Liver enzyme levels and viral load are checked every three to six months. For people at elevated risk of liver cancer, periodic ultrasound imaging screens for tumors while they’re still small and treatable.
Prevention Through Vaccination
The hepatitis B vaccine is one of the most effective vaccines available and is the primary reason chronic HBV rates have dropped sharply in countries with universal childhood immunization programs. A complete vaccine series provides immunity that lasts at least 30 years when started in infancy, and booster doses are not currently recommended for healthy people who completed the series.
For babies born to mothers with hepatitis B, vaccination within 12 hours of birth, combined with an injection of hepatitis B immune globulin, dramatically reduces the risk of mother-to-child transmission. This combination is the cornerstone of global efforts to eliminate new chronic infections.